Similar articles

• Clinical characteristics related to methotrexate-induced pancytopenia.

  Ohosone Y, Okano Y, Kameda H, Hama N, Mimori T, Akizuki M, Ikeda Y. Ohosone Y, et al. Clin Rheumatol. 1997 May;16(3):321-3. doi: 10.1007/BF02238974. Clin Rheumatol. 1997. PMID: 9184276 Clinical Trial. No abstract available.
• Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ureña et al.

  Berthelot JM, Maugars Y, Prost A. Berthelot JM, et al. Arthritis Rheum. 1997 Jan;40(1):193-4; author reply 195-6. doi: 10.1002/art.1780400129. Arthritis Rheum. 1997. PMID: 9008619 Review. No abstract available.
• [Serious adverse effects of methotrexate therapy in patients with rheumatic arthritis].

  Purokivi M, Myllykangas-Luosujärvi R, Jantunen E. Purokivi M, et al. Duodecim. 1998;114(21):2187-90. Duodecim. 1998. PMID: 11757107 Finnish. No abstract available.
• Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ureña et al.

  Nygaard H. Nygaard H. Arthritis Rheum. 1997 Jan;40(1):194-5; author reply 195-6. doi: 10.1002/art.1780400130. Arthritis Rheum. 1997. PMID: 9008620 No abstract available.
• Methotrexate for rheumatoid arthritis patients who are on hemodialysis.

  Al-Hasani H, Roussou E. Al-Hasani H, et al. Rheumatol Int. 2011 Dec;31(12):1545-7. doi: 10.1007/s00296-011-2041-5. Epub 2011 Jul 22. Rheumatol Int. 2011. PMID: 21833520 Review.